To further evaluate whether inhibiting FAP can reverse T2DM-induced HFpEF, we extensively screened FAP inhibitors that can be used for clinical translation and found that Talabostat inhibited activity and level of FAP, which has been used in phase I clinical trials [16]. The gene discussed is FAP; the disease is type 2 diabetes mellitus.